 |
|
Topical Metronidazole Maintains Remissions of Rosacea
Mark V. Dahl, MD;
H. Irving Katz, MD;
Gerald G. Krueger, MD;
Larry E. Millikan, MD;
Richard B. Odom, MD;
Frank Parker, MD;
John E. Wolf, Jr, MD;
Raza Aly, PhD;
Charlene Bayles, BS;
Brenda Reusser, BA;
Melissa Weidner, RN;
Edward Coleman, MS;
Robert Patrignelli, MD;
Michael R. Tuley, PhD;
Michael O. Baker, BS;
James H. Herndon, Jr, MD;
Janusz M. Czernielewski, MD
Arch Dermatol. 1998;134:679-683.
Background Rosacea is a chronic skin disease that requires long-term therapy. Oral antibiotics and topical metronidazole successfully treat rosacea. Because long-term use of systemic antibiotics carries risks for systemic complications and adverse reactions, topical treatments are preferred.
Objective To determine if the use of topical metronidazole gel (Metrogel) could prevent relapse of moderate to severe rosacea.
Design A combination of oral tetracycline and topical metronidazole gel was used to treat 113 subjects with rosacea (open portion of the study). Successfully treated subjects (n= 88) entered a randomized, double-blind, placebo-controlled study applying either 0.75% topical metronidazole gel (active agent) or topical metronidazole vehicle gel (placebo) twice daily (blinded portion of the study).
Setting Subjects were enrolled at 6 separate sites in large cities at sites associated with major medical centers.
Subjects One hundred thirteen subjects with at least 6 inflammatory papules and pustules, moderate to severe facial erythema, and telangiectasia entered the open phase of the study. Eighty-eight subjects responded to treatment with systemic tetracycline and topical metronidazole gel as measured by at least a 70% reduction in the number of inflammatory lesions. These subjects were randomized to receive 1 of 2 treatments: either 0.75% metronidazole gel or placebo gel.
Interventions Subjects were evaluated monthly for up to 6 months to determine relapse rates.
Main Outcome Measures Inflammatory papules and pustules were counted at each visit. Relapse was determined by the appearance of a clinically significant increase in the number of papules and pustules. Prominence of telangiectases and dryness (roughness and scaling) were also observed.
Results In the open phase, treatment with tetracycline and metronidazole gel eliminated all papules and pustules in 67 subjects (59%). The faces of 104 subjects (92%) displayed fewer papules and pustules after treatment, and 82 subjects (73%) exhibited less erythema. In the randomized double-blind phase, the use of topical metronidazole significantly prolonged the disease-free interval and minimized recurrence compared with subjects treated with the vehicle. Eighteen (42%) of 43 subjects applying the vehicle experienced relapse, compared with 9 (23%) of 39 subjects applying metronidazole gel (P<.05). The metronidazole group had fewer papules and/or pustules after 6 months of treatment (P<.01). Relapse of erythema also occurred less often in subjects treated with metronidazole (74% vs 55%).
Conclusion In a majority of subjects studied, continued treatment with metronidazole gel alone maintains remission of moderate to severe rosacea induced by treatment with oral tetracycline and topical metronidazole gel.
From the Department of Dermatology, University of Minnesota, Minneapolis (Dr Dahl); Minnesota Clinical Study Center, Minneapolis (Dr Katz); the Division of Dermatology, University of Utah, Salt Lake City (Dr Krueger and Ms Weidner); the Department of Dermatology, Tulane University, New Orleans, La (Drs Millikan and Patrignelli and Mr Coleman); the Department of Dermatology, University of California at San Francisco (Drs Odom and Aly and Ms Bayles); the Department of Dermatology, Oregon Health Sciences University, Portland (Dr Parker); the Department of Dermatology, Baylor Medical Center, Houston, Tex (Dr Wolf and Ms Reusser); Southwestern Medical School, Dallas, Tex (Dr Herndon); and Galderma Laboratories Inc, Fort Worth, Tex (Drs Tuley and Czernielewski and Mr Baker). Dr Herndon is a paid consultant for Galderma Laboratories Inc. Drs Tuley and Czernielewski and Mr Baker are employees of Galderma Laboratories Inc.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Rosacea
Powell
NEJM 2005;352:793-803.
FULL TEXT
What Proportion of Dermatological Patients Receive Evidence-Based Treatment?
Abeni et al.
Arch Dermatol 2001;137:771-776.
ABSTRACT
| FULL TEXT
Use of Topical Products for Maintaining Remission in Rosacea
Wilkin
Arch Dermatol 1999;135:79-80.
FULL TEXT
Topical Metronidazole Prevents Relapse of Rosacea
Journal Watch Dermatology 1998;1998:3-3.
FULL TEXT
Metronidazole Gel Helps Prevent Rosacea Relapse
JWatch General 1998;1998:4-4.
FULL TEXT
|
